Elevance Health (ELV) Q3 2025 Earnings

Yes. Elevance Health reported Q3 2025 earnings of $6.03 a share on Oct 21, 2025, beating the $4.94 consensus estimate by 22.0%. Revenue was $50.7B against a $49.5B estimate.

Elevance Health delivered a strong third-quarter beat in Q3 2025, posting adjusted diluted EPS of $6.03 against a consensus estimate of $4.94, a 22.01% positive surprise, while revenue of $50.71 billion topped expectations by 2.45% and grew 12.3% year over year. The standout driver behind the earnings outperformance was the continued expansion of Carelon, whose operating revenue surged 33% to $18.30 billion, powered by home health and pharmacy acquisitions and scaling risk-based solutions, helping offset a sharp compression in Health Benefits segment margins tied to elevated Medicare cost trends and Inflation Reduction Act-related Part D seasonality. The benefit expense ratio rose to 91.3%, reflecting anticipated but pronounced cost pressures, particularly in the Medicare business. Despite near-term margin headwinds, institutional interest in the stock has remained constructive, with analysts maintaining a broadly positive consensus outlook. Elevance reaffirmed its full-year 2025 guidance, projecting adjusted diluted EPS of approximately $30.00 and a benefit expense ratio of approximately 90.0%, signaling confidence in execution as management positions the company for 2026.